, Volume 24, Issue 7, pp 631–642 | Cite as

Economic Models of Antiretroviral Therapy

Searching for the Optimal Strategy
Current Opinion


The diffusion of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in the US in 1996 and 1997 reduced the number of deaths attributable to HIV disease and changed the way we think about the illness. Today, HIV disease may be deemed a fairly expensive chronic condition rather than an intolerably expensive fatal illness.

Although most studies have found that patients receiving new drug therapies are hospitalised less frequently than patients who received early drug therapies, it is unclear whether the diffusion of new drug therapies has increased or decreased the annual cost of care. However, it is evident that the diffusion of new drug therapies has increased the lifetime cost of care.

Analysts rely on models to simulate the course and cost of HIV disease. This study reviews the evolution of these models, paying particular attention to how these models estimate the cost of care. The primary findings of this review are that the economic data used in these models are often too imprecise to accurately identify the cost of each disease stage and are almost always outdated. Moreover, it was found that estimates of drug costs in these models may not accurately reflect actual expenditures.



The opinions expressed are those of the author and not those of AHRQ. The author has no conflicts of interest to report and received no funding for the preparation of this article.


  1. 1.
    Moyle MJ, Gazzard BG. A risk-benefit assessment of HIV protease inhibitors. Drug Saf 1999; 20: 299–321PubMedCrossRefGoogle Scholar
  2. 2.
    Sonnenberg FA, Beck RJ. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322–328PubMedCrossRefGoogle Scholar
  3. 3.
    Beck EJ, Miners AH, Tolley K. The cost of HIV treatment and care: a global review. Pharmacoeconomics 2001; 19: 13–39PubMedCrossRefGoogle Scholar
  4. 4.
    Moore RD, Bartlett JG. Cormination antiretroviral therapy in HIV infection: an economic perspective. Pharmacoeconomics 1996; 10: 109–113PubMedCrossRefGoogle Scholar
  5. 5.
    Schackman BR, Goldie SJ, Freedberg KA, et al. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002; 22: 27–38PubMedGoogle Scholar
  6. 6.
    Yazdanpanah Y, Goldie SJ, Losina E, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther 2002; 7: 257–266PubMedGoogle Scholar
  7. 7.
    Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993; 270: 474–478PubMedCrossRefGoogle Scholar
  8. 8.
    Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Reports 1987; 102: 5–17PubMedGoogle Scholar
  9. 9.
    Scitovsky AA. Studying the cost of HIV-related illnesses: reflections on the moving target. Milbank Q 1989; 67: 318–326PubMedCrossRefGoogle Scholar
  10. 10.
    Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. N Engl J Med 1998; 339: 1897–1904PubMedCrossRefGoogle Scholar
  11. 11.
    Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13: 963–969PubMedCrossRefGoogle Scholar
  12. 12.
    Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV cost and services utilization study. JAMA 1999; 281: 2305–2315PubMedCrossRefGoogle Scholar
  13. 13.
    Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824–831PubMedCrossRefGoogle Scholar
  14. 14.
    Beck EJ, Mandalia S, Gaudreault M, et al. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991–2001. AIDS 2004; 18: 2411–2418PubMedGoogle Scholar
  15. 15.
    Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States: an analysis of cost-effectiveness. N Engl J Med 2005; 352: 586–595PubMedCrossRefGoogle Scholar
  16. 16.
    Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005; 352 (6): 570–585PubMedCrossRefGoogle Scholar
  17. 17.
    Moore RD. Cost-effectiveness of combination HIV therapy: 3 years later. Pharmacoeconomics 2000; 17: 325–331PubMedCrossRefGoogle Scholar
  18. 18.
    Mellors JW, Rinaldo Jr CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167–1170PubMedCrossRefGoogle Scholar
  19. 19.
    Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946–954PubMedGoogle Scholar
  20. 20.
    Andrulis DP, Weslowski VB, Hintz E, et al. Comparisons of hospital care for patients with AIDS and other HIV-related conditions. JAMA 1992; 267: 2482–2486PubMedCrossRefGoogle Scholar
  21. 21.
    Hellinger FJ. The cost and financing of care for persons with HIV disease: an overview. Health Care Financ Rev 1998; 19: 5–18PubMedGoogle Scholar
  22. 22.
    US Food and Drug Administration, USDHHHS. Drugs used in the treatment of HIV infection [online]. Available from URL: [Accessed 2006 Jun 14]Google Scholar
  23. 23.
    Hardy AM, Starcher TE, Morgan WM. The economic impact of the first 10 000 cases of acquired immunodeficiency syndrome in the United States. JAMA 1986; 255: 209–211PubMedCrossRefGoogle Scholar
  24. 24.
    Schackman BR, Goldie SJ, Weinstein MC, et al. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health 2001; 91: 1456–1463PubMedCrossRefGoogle Scholar
  25. 25.
    Montessori V, Press N, Harris M, et al. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004 Jan 20; 170 (2): 229–238PubMedGoogle Scholar
  26. 26.
    Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse effects. Drug Saf 2005; 28: 1075–1083PubMedCrossRefGoogle Scholar
  27. 27.
    Sax PE, Gathe Jr JC. Beyond efficacy: the impact of combination antiretroviral therapy on quality of life. AIDS Patient Care STDS 2005; 19: 563–576PubMedCrossRefGoogle Scholar
  28. 28.
    Umeh OC, Currier JS. Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Current HIV/AIDS Rep 2005; 2 (3): 132–139CrossRefGoogle Scholar
  29. 29.
    Tapper ML, Aexner C, Fron JJ, et al. Simplifying antiretroviral therapy. AIDS Read 2004; 14: 367–371Google Scholar
  30. 30.
    Portsmouth SD, Osorio J, McCormick K, et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005; 6: 185–190PubMedCrossRefGoogle Scholar
  31. 31.
    Kates J, Penner M, Cruttsinger-Perry B, et al. National ADAP Monitoring Project Report, Kaiser Family Foundation and the National Association of State and Territorial AIDS Directors. Washingon, DC: Kaiser Family Foundation, 2006 [online]. Available from URL: [Accessed 2006 Jun 14]Google Scholar
  32. 32.
    Bozzette SA, Geoffrey J, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344: 817–823PubMedCrossRefGoogle Scholar
  33. 33.
    Aldridge C, Davis D, Doyle A. National ADAP monitoring project: interim technical report. Menlo Park (CA): The Henry J. Kaiser Family Foundation, 2002Google Scholar
  34. 34.
    Hellinger FJ, Encinosa WE. Antiretroviral therapy and health care utilization: a study of privately insured men and women with HIV disease. Health Serv Res 2004; 39: 949–967PubMedCrossRefGoogle Scholar
  35. 35.
    Duggans MG, Evans WN. Estimating the impact of medical innovation: the case of HIV antiretroviral treatments. National Bureau of Economic Research (NBER) Working Paper 1109. Cambridge (MA): National Bureau of Economic Research, 2005Google Scholar
  36. 36.
    Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–860PubMedCrossRefGoogle Scholar
  37. 37.
    US Centers for Disease Control and Prevention. HIV/AIDS surveillance report: US HIV and AIDS cases reported through June 2001, vol. 13 no. 1, 2001 [online]. Available from URL: [Accessed 2006 Jun 14]Google Scholar
  38. 38.
    Risebrough N, Oh P, Rachlis A, et al. Economic evaluation of triple ART with indinavir or abacavir and ZDV+3TC compared to dual therapy ZDV+3TC [abstract no. 103]. 6th Conference on Retroviruses and Opportunistic Infection; 1999 Jan 31–Feb 4; Chicago (IL)Google Scholar
  39. 39.
    Miners AH, Sabin CA, Trueman P, et al. Assessing the cost-effectiveness of highly active antiretroviral therapy for adults with HIV in England. HIV Med 2001; 2: 52–58PubMedCrossRefGoogle Scholar
  40. 40.
    Plosker GL, Perry CM, Goa KL. Efavirenz: a pharmacoeconomic review of its use in HIV infection. Pharmacoeconomics 2001; 19: 421–436PubMedCrossRefGoogle Scholar
  41. 41.
    Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 54–62PubMedCrossRefGoogle Scholar
  42. 42.
    Mauskopf J, Kitahata M, Kauf T, et al. HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr 2005 Aug 15; 39 (5): 562–569PubMedGoogle Scholar
  43. 43.
    Richter A, Hauber B, Simpson K, et al. A Monte Carlo simulation for modeling outcomes of AIDS treatment regimens. Pharmacoeconomics 2002; 20 (4): 215–226PubMedCrossRefGoogle Scholar
  44. 44.
    Gable C, Tierce J, SimisonD, et al. Costs of HIV/AIDS at CD4+ counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr Hum Retrovirol 1996 Aug 1; 12 (4): 413–420PubMedCrossRefGoogle Scholar
  45. 45.
    Drug topics red book. Montvale (NJ): Medical Economics, 2001Google Scholar
  46. 46.
    US Department of Health and Human Services, Office of the Inspector General. Cost containment of Medicaid HIV/AIDS drug expenditures. Report No. OEI-05-99-0611. Washington, DC: 2001 JulGoogle Scholar
  47. 47.
    Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725–733PubMedCrossRefGoogle Scholar
  48. 48.
    Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, the Netherlands, Canada and Australia Study. JAMA 1998; 279: 930–937PubMedCrossRefGoogle Scholar
  49. 49.
    Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81–87PubMedGoogle Scholar
  50. 50.
    Yazdanpanah Y. Costs associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53: 558–561PubMedCrossRefGoogle Scholar
  51. 51.
    Keiser P, Nassar N, Kvanli MB, et al. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J Acquir Immune Defic Syndr 2001; 27: 14–19PubMedGoogle Scholar
  52. 52.
    Roberts RR, Rydman RJ, Gorosh K, et al. Actual costs of HIV/AIDS care. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4–8; Chicago (IL)Google Scholar
  53. 53.
    King IT, Justice AC, Roberts MS, et al. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis Making 2003; 23: 9–20PubMedCrossRefGoogle Scholar
  54. 54.
    Amundsen EJ, Fekjaer H. Progression to AIDS slowed even more after the first two years with highly active antiretoriviral therapy. Scand J Public Health 2001; 31: 312–318CrossRefGoogle Scholar
  55. 55.
    Bonjoch A, Paredes R, Galvez J, et al. Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1 infected patients treated with successful first-line HAART. J Acquir Immune Defic Syndr 2005; 339: 1897–1904Google Scholar
  56. 56.
    Jacobson LP, Phair J, Margolick JB, et al. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Fpidemiol 2002; 155: 760–770CrossRefGoogle Scholar
  57. 57.
    Vergu E, Mallet A, Golmard L. Available clinical markers of treatment outcome integrated in mathematical models to guide therapy in HIV infection. J Antimicrob Chemother 2004; 53 (2), 140–143PubMedCrossRefGoogle Scholar
  58. 58.
    Haubrich R, Demeter L. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr 2001; 26 (1): S51–S59PubMedGoogle Scholar
  59. 59.
    Hanna GJ, D’Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 2001; 32: 774–782PubMedCrossRefGoogle Scholar
  60. 60.
    Torre D, Tarmini R. Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials 2002; 3 (1): 1–8PubMedCrossRefGoogle Scholar
  61. 61.
    Weinstein MC, Goldie SJ, Losina E, et al. Resistance testing to guide the choice of second-line therapy in HIV: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134: 440–450PubMedGoogle Scholar
  62. 62.
    Pinkerton SD, Holtgrave DR. Economic impact of delaying or preventing AIDS in persons with HIV. Am J Manag Care 1999; 5: 289–298PubMedGoogle Scholar
  63. 63.
    Schackman BR, Freedberg KA, Weinstein Me, et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 2002; 162: 2478–2486PubMedCrossRefGoogle Scholar
  64. 64.
    Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naïve HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005 Nov 1; 41 (9): 1316–1323PubMedCrossRefGoogle Scholar
  65. 65.
    Lundgren JD, Ledergerber B, Hermans P, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results for the EuroSIDA study. J Infect Dis 2002; 185: 178–187PubMedCrossRefGoogle Scholar
  66. 66.
    Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119–129PubMedCrossRefGoogle Scholar
  67. 67.
    Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 Suppl. 1: S5–S37PubMedCrossRefGoogle Scholar
  68. 68.
    Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362: 2002–2011PubMedCrossRefGoogle Scholar
  69. 69.
    Cook AE. Strategies for containing drug costs: implications for a medicare benefit. Health Care Finane Rev 1999; 20: 29–37Google Scholar
  70. 70.
    The HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr 2002; 30: 21–26CrossRefGoogle Scholar
  71. 71.
    Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of HAART persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005; 38: 96–103PubMedCrossRefGoogle Scholar
  72. 72.
    Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000–2002. Med Care 2005 Sep; 43 (9 Suppl.): III-40–III-52Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Center for Delivery, Organization and MarketsAgency for Healthcare Research and Quality (AHRQ)RockvilleUSA

Personalised recommendations